Funding for this research was provided by:
Boehringer Ingelheim (N/A)
Received: 25 May 2021
Accepted: 20 December 2021
First Online: 10 January 2022
: The SENSCIS® trial was conducted in accordance with the trial protocol, the principles of the Declaration of Helsinki and the Harmonised Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonisation, and was approved by local authorities. Written informed consent was obtained from all patients before study entry.
: Not applicable.
: MK reports consultancy fees from Boehringer Ingelheim (BI), Roche and Galapagos, outside the submitted work. FDG reports research grants from Capella Biosciences, Mitsubishi-Tanabe, Chemomab and Kymab; and consultancy fees from Actelion, BI, AstraZeneca, Mitsubishi-Tanabe, Capella and Chemomab, outside the current work. DK reports research grants from Immune Tolerance Network, Bayer, Horizon and Pfizer; consultancy fees from Acceleron, Actelion, Abbvie, Amgen, Bayer, BI, CSL Behring, Corbus, Gilead, Galapagos, Genentech/Roche, GlaxoSmithKline, Horizon, Merck, Mitsubishi Tanabe Pharma, Sanofi-Aventis and United Therapeutics; and employment at Eicos Science/CiviBioPharma, outside the submitted work. WW has nothing to disclose. LKH reports research grants from BI, Corbus, Cumberland, CSL Behring, Kadmon and Medpace; and advisory board fees from BI, outside the submitted work. YA reports consultancy fees from BI, during the conduct of the study. MA is an employee of Boehringer Ingelheim International GmbH. NS was an employee of Boehringer Ingelheim International GmbH at the time of this study. CS is an employee of Boehringer Ingelheim Pharma GmbH & Co. KG. CM is an employee of mainanalytics GmbH, which is a service provider contracted by BI.